2025 promise delivered; 2026 targets in sight
27/02/26 -"bioMerieux’s Q4 sales met expectations, with top-line growth driven by both segments. Management fulfilled its 2025 commitments and provided 2026 targets aligned with the GO28 ambitions. This ..."
Pages
64
Language
English
Published on
27/02/26
You may also be interested by these reports :
05/03/26
Elekta’s Q3 profitability exceeded consensus expectations. Organic sales growth was recorded in EMEA and APAC, while the Americas exhibited weakness. ...
05/03/26
Amplifon reported another quarterly performance miss, with both sales and profitability falling short of the company-compiled consensus. Although the ...
04/03/26
We appreciate Clariane’s stronger-than-expected deleveraging and consider the 2026 targets easily achievable. However, the thin but consensus-beating ...
03/03/26
Given the company’s more tangible operational normalisation and earlier-than-expected exit from the accelerated safeguard plan, incorporating ...